Establishing a New Core Product Lineup Alongside Dialysis-Related Products
First written in FY2017. 5 of 7 entries say "Restated". Latest entry: FY2026.
Fuso Pharmaceutical Industries moved to the "Worse" side of this theme in 2026.
The whole theme swung hardest in 2026: 1 of 7 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「As the company’s vision for 2030, we have set the goal of becoming an indispensable company that supports society through healthcare, both as a manufacturer of essential medicines providing thorough quality control and a stable, sustainable supply, and as a specialty pharmaceutical company addressing unmet medical needs in the fields of nephrology and urology.」
The previous direction of establishing new core product groups alongside dialysis-related products has been clarified as pursuing both a role as a manufacturer of essential medicines and a specialty pharmaceutical company in nephrology and urology toward 2030. - FY2024RestatedAnnual report
「To address the current challenging business environment, we will develop and nurture products that address new medical needs, establish new core product groups alongside our dialysis-related products, and pursue stable growth over the long term.」
The company continues to pursue a medium- to long-term strategy of establishing new core product groups alongside its dialysis-related products and achieving stable growth. - FY2022RestatedAnnual report
「By developing and nurturing products that address new medical needs, we will establish new core product groups alongside our dialysis-related products and pursue stable growth over the long term.」
The company continues to pursue a medium- to long-term strategy of establishing new core product groups alongside its dialysis-related products. - FY2021RestatedAnnual report
「By developing and nurturing products that address new medical needs, we will establish new core product groups alongside our dialysis-related products and pursue stable growth over the long term.」
The company continues to pursue a medium- to long-term strategy of establishing new core product groups alongside its dialysis-related products. - FY2019RestatedAnnual report
「By developing and nurturing products that address new medical needs, we will establish new core product groups alongside our dialysis-related products and pursue stable growth over the long term.」
The company continues to pursue a medium- to long-term strategy of establishing new core product groups alongside its dialysis-related products. - FY2018RestatedAnnual report
「By developing and nurturing products that address new medical needs, we will establish new core product groups alongside our dialysis-related products and pursue stable growth over the long term.」
The company continues to pursue a medium- to long-term strategy of establishing new core product groups alongside its dialysis-related products. - FY2017First statedAnnual report
「By developing and nurturing products that address new medical needs, we will establish new core product groups alongside our dialysis-related products and pursue stable growth over the long term.」
The company has set out a medium- to long-term strategy to establish new core product groups alongside its dialysis-related products by developing and nurturing products that address new medical needs.